Archives of Clinical Infectious Diseases

Published by: Kowsar
Crossmark

Relationship Between the Serum Level of C-Reactive Protein and Severity and Outcomes of Community-acquired Pneumonia

Farhad Malek 1 , Ali Gohari 1 , * , Majid Mirmohammadkhani 2 and Farnaz Ardiani 3
Authors Information
1 Department of Internal Medicine, Semnan University of Medical Sciences, Semnan, Iran
2 Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran
3 Semnan University of Medical Sciences, Semnan, Iran
Article information
  • Archives of Clinical Infectious Diseases: 14 (2); e63893
  • Published Online: April 24, 2019
  • Article Type: Research Article
  • Received: November 9, 2017
  • Revised: January 26, 2018
  • Accepted: February 17, 2019
  • DOI: 10.5812/archcid.63893

To Cite: Malek F, Gohari A, Mirmohammadkhani M, Ardiani F. Relationship Between the Serum Level of C-Reactive Protein and Severity and Outcomes of Community-acquired Pneumonia, Arch Clin Infect Dis. Online ahead of Print ; 14(2):e63893. doi: 10.5812/archcid.63893.

Abstract
Copyright © 2019, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's principles of internal medicine. 18th ed. New York: McGraw-Hill; 2012.
  • 2. Hoyert DL, Heron MP, Murphy SL, Kung HC. Deaths: Final data for 2003. Nat Vit Stat Rep. 2006;54:30-8. doi: 10.1037/e518032006-001.
  • 3. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F, Epivac Study Group . Epidemiology of community-acquired pneumonia in older adults: A population-based study. Respir Med. 2009;103(2):309-16. doi: 10.1016/j.rmed.2008.08.006. [PubMed: 18804355].
  • 4. Hansen V, Oren E, Dennis LK, Brown HE. Infectious disease mortality trends in the United States, 1980-2014. JAMA. 2016;316(20):2149-51. doi: 10.1001/jama.2016.12423. [PubMed: 27893119].
  • 5. Hifumi T, Jinbo I, Okada I, Kiriu N, Kato H, Koido Y, et al. The impact of age on outcomes of elderly ED patients ventilated due to community acquired pneumonia. Am J Emerg Med. 2015;33(2):277-81. doi: 10.1016/j.ajem.2014.10.046. [PubMed: 25541226].
  • 6. Gibson GJ, Loddenkemper R, Lundback B, Sibille Y. Respiratory health and disease in Europe: The new European lung white book. Eur Respir J. 2013;42(3):559-63. doi: 10.1183/09031936.00105513. [PubMed: 24000245].
  • 7. Kothe H, Bauer T, Marre R, Suttorp N, Welte T, Dalhoff K. Outcome of community-acquired pneumonia: Influence of age, residence status and antimicrobial treatment. Eur Respirat J. 2008;32(1):139-46. doi: 10.1183/09031936.00092507.
  • 8. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008;133(3):610-7. doi: 10.1378/chest.07-1456. [PubMed: 17989157].
  • 9. España PP, Capelastegui A, Quintana JM, Bilbao A, Diez R, Pascual S, et al. Validation and comparison of SCAP as a predictive score for identifying low-risk patients in community-acquired pneumonia. J Infect. 2010;60(2):106-13. doi: 10.1016/j.jinf.2009.11.013.
  • 10. Benisi R, Bayat-Makoo Z, Mobaiyen H. Prognostic factors and outcome of patients hospitalized with community acquired Pneumonia. J Analyt Res Clin Med. 2018;6(2):86-92. doi: 10.15171/jarcm.2018.013.
  • 11. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med. 2011;183(11):1561-8. doi: 10.1164/rccm.201007-1167OC. [PubMed: 21297074].
  • 12. Shan J, Chen HL, Zhu JH. Diagnostic accuracy of clinical pulmonary infection score for ventilator-associated pneumonia: A meta-analysis. Respirat Care. 2011;56(8):1087-94. doi: 10.4187/respcare.01097.
  • 13. Müller NL, Franquet T, Lee KS, Silva CI. Imaging of pulmonary infections. Lippincott Williams & Wilkins; 2007.
  • 14. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al. SMART-COP: A tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47(3):375-84. doi: 10.1086/589754. [PubMed: 18558884].
  • 15. Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax. 2006;61(5):419-24. doi: 10.1136/thx.2005.051326. [PubMed: 16449258]. [PubMed Central: PMC2111174].
  • 16. Singanayagam A, Chalmers JD, Hill AT. Severity assessment in community-acquired pneumonia: A review. Qjm. 2009;102(6):379-88. doi: 10.1093/qjmed/hcp027.
  • 17. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and practice of infectious diseases. Churchill Livingstone; 2010.
  • 18. Frei CR, Bell AM, Traugott KA, Jaso TC, Daniels KR, Mortensen EM, et al. A clinical pathway for community-acquired pneumonia: An observational cohort study. BMC Infect Dis. 2011;11(1). doi: 10.1186/1471-2334-11-188.
  • 19. Leroy O, Mikolajczyk D, Devos P, Chiche A, Grunderbeeck NV, Boussekey N, et al. Validation of a prediction rule for prognosis of severe community-acquired pneumonia. Open Respir Med J. 2008;2:67-71. doi: 10.2174/1874306400802010067. [PubMed: 19365534]. [PubMed Central: PMC2606649].
  • 20. Menendez R, Martinez R, Reyes S, Mensa J, Filella X, Marcos MA, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009;64(7):587-91. doi: 10.1136/thx.2008.105312. [PubMed: 19131448].
  • 21. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med. 2008;121(3):219-25. doi: 10.1016/j.amjmed.2007.10.033. [PubMed: 18328306].
  • 22. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: Diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. 2007;30(3):556-73. doi: 10.1183/09031936.00166106. [PubMed: 17766633].
  • 23. Torres A, Ramirez P, Montull B, Menéndez R. Biomarkers and community-acquired pneumonia: Tailoring management with biological data. Seminar Respirat Crit Care Med. 2012;33(3):266-71. doi: 10.1055/s-0032-1315638.
  • 24. Akram AR, Chalmers JD, Taylor JK, Rutherford J, Singanayagam A, Hill AT. An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia. Clin Microbiol Infect. 2013;19(12):1174-80. doi: 10.1111/1469-0691.12173. [PubMed: 23438068].
  • 25. Eisenhut M. A persistently elevated C-reactive protein level in pneumonia may indicate empyema. Crit Care. 2008;12(1):409. author reply 409. doi: 10.1186/cc6204. [PubMed: 18341702]. [PubMed Central: PMC2374620].
  • 26. Coelho LM, Salluh JIF, Soares M, Bozza FA, Verdeal JCR, Castro-Faria-Neto HC, et al. Patterns of C-reactive protein RATIO response in severe community-acquired pneumonia: A cohort study. Crit Care. 2012;16(2):R53. doi: 10.1186/cc11291.
  • 27. Espana PP, Capelastegui A, Bilbao A, Diez R, Izquierdo F, Lopez de Goicoetxea MJ, et al. Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2012;31(12):3397-405. doi: 10.1007/s10096-012-1708-5. [PubMed: 23010902].
  • 28. Hohenthal U, Hurme S, Helenius H, Heiro M, Meurman O, Nikoskelainen J, et al. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. Clin Microbiol Infect. 2009;15(11):1026-32. doi: 10.1111/j.1469-0691.2009.02856.x. [PubMed: 19548923].
  • 29. Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008;63(5):447-52. doi: 10.1136/thx.2007.086785. [PubMed: 18245147].
  • 30. Coelho L, Povoa P, Almeida E, Fernandes A, Mealha R, Moreira P, et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care. 2007;11(4):R92. doi: 10.1186/cc6105. [PubMed: 17723153]. [PubMed Central: PMC2206486].
  • 31. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: Update 2009. Thorax. 2009;64 Suppl 3:iii1-55. doi: 10.1136/thx.2009.121434. [PubMed: 19783532].
  • 32. Ott SR, Hauptmeier BM, Ernen C, Lepper PM, Nuesch E, Pletz MW, et al. Treatment failure in pneumonia: Impact of antibiotic treatment and cost analysis. Eur Respirat J. 2011;39(3):611-8. doi: 10.1183/09031936.00098411.
  • 33. Chen X. Causes and management of initial treatment failure in patients with community-acquired pneumonia. Commun Acquir Infect. 2014;1(2):65. doi: 10.4103/2225-6482.147665.
  • 34. Vukadinovic D, Samardzic N, Jankovic S, Tomic-Smiljanic M, Pavlovic R, Stefanovic S. Factors associated with early treatment failure in adult hospitalized patients with community-acquired pneumonia. Vojnosanitetski pregled. 2017;74(9):803-13. doi: 10.2298/vsp160211085v.
  • 35. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045. doi: 10.1038/nrdp.2016.45. [PubMed: 28117397]. [PubMed Central: PMC5538252].
  • 36. Moldoveanu B, Otmishi P, Jani P, Walker J, Sarmiento X, Guardiola J, et al. Inflammatory mechanisms in the lung. J Inflamm Res. 2009;2:1-11. doi: 10.2147/JIR.S4385. [PubMed: 22096348]. [PubMed Central: PMC3218724].
  • 37. Le Bel J, Hausfater P, Chenevier-Gobeaux C, Blanc FX, Benjoar M, Ficko C, et al. Diagnostic accuracy of C-reactive protein and procalcitonin in suspected community-acquired pneumonia adults visiting emergency department and having a systematic thoracic CT scan. Crit Care. 2015;19(1). doi: 10.1186/s13054-015-1083-6.
  • 38. Walters G, Liu HS, Gemza M, Rauf F. Does the serum C-reactive protein (CRP) predict adverse outcomes in patients admitted with community acquired pneumonia? Eur Respirat J. 2011;64(3):1-55.
  • 39. Makarevich A, Omelyanenko O, Amelchenko E, Rybina T. C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis. Eur Respirat J. 2011;38:1470.

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments